Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 20, 20 December 2023
Open
Access | Article
Treatment of Alzheimer’s disease based on new drugs
* Author to whom correspondence should be addressed.
Abstract
It is well-known that Alzheimer’s disease (AD) is a chronic neurodegeneration characterized by memory impairment, cognitive complexity, language impairment, mood swings, and behavioral abnormalities. The AD is related to a variety of factors and has been associated with circumstances, genes, generations and genders. The mechanism of pathogenesis is also unclear, and there are several hypothesis theories. The more convincing one is the deposition of amyloid. Although there is no one drug that can cure the AD completely, there are approved drugs that alleviate the development of the AD by preventing the breakdown of acetylcholinesterase and increasing the nerve cells that transmit messages. The development of new drugs and their use in the treatment of AD has received increasing attention. In this research, six drugs will be focused on, which are aduhelm, aricept, exelon, leqembi, namenda, and namzaric. Compared with single-target drugs, multi-target drugs can target different physiological aspects of the disease and have the advantages of fewer adverse effects, lower clinical doses and significant efficacy. Because their therapeutic mechanisms are different, patients can select the most appropriate drugs for different conditions of the AD according to the symptoms of the disease. Based on the current treatments, there is no way to cure the AD, hoping people could find a full cure for AD in the future.
Keywords
Alzheimer’s disease, mechanism, drug therapy
References
1. Tatulian S. A., "Challenges and hopes for Alzheimer's disease," Drug discovery today 27, 1027–1043 (2022).
2. Ossenkoppele, R., van der Kant, R. and Hansson, O., "Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials," The Lancet. Neurology 21, 726–734 (2022).
3. Jack C. R., Jr, "Advances in Alzheimer's disease research over the past two decades," The Lancet. Neurology 21, 866–869 (2022).
4. Pai-Dhungat J., "Kary Mullis-inventor of PCR," The Journal of the Association of Physicians of India 67, 96 (2019).
5. Knorz, A. L. and Quante, A. "Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review," Journal of geriatric psychiatry and neurology 35, 475–486 (2022).
6. Tanzi R. E., "FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease," ACS chemical neuroscience 12, 2714–2715 (2021).
7. Garay, R. P. and Grossberg, G. T., "AVP-786 for the treatment of agitation in dementia of the Alzheimer's type," Expert opinion on investigational drugs 26, 121–132 (2017).
8. Nirogi, R., Ieni, J., Goyal, V. K., Ravula, J., Jetta, S., Shinde, A., Jayarajan, P., Benade, V., Palacharla, V. R. C., Dogiparti, D. K., Jasti, V., Atri, A. and Cummings, J., "Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study," Alzheimer's & dementia 8, e12307 (2022)
9. Zhang, H., Zhao, Y., Yu, M., Zhao, Z., Liu, P., Cheng, H., Ji, Y., Jin, Y., Sun, B., Zhou, J. and Ding, Y., "Reassembly of native components with donepezil to execute dual-missions in Alzheimer's disease therapy," Journal of controlled release 296, 14–28 (2019).
10. Mohamed, S. M., Khalil, W. F. and Abdel-Atty, M. E. A. E. F., "Effect of Curcumin, Exelon and their Combination on Brain in Alzheimer’s Disease-Induced Rats," Journal of Advances in Medicine and Medical Research 33, 65–78 (2021).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-213-8
- ISBN (Online)
- 978-1-83558-214-5
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/20/20230703
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited